Dr. Zhenwen Zhao is currently working at Institute of Chemistry, Chinese Academy of Sciences (ICCAS). He is a recipient of the “Outstanding Young Scholars” from ICCAS (2012). Zhenwen Zhao received his Ph. D in Analytical Chemistry from Institute of Chemistry, Chinese Academy of Science in Jun 2005, where his Ph. D training focused on the MALDI-TOF MS for analysis of polysaccharides, organic compounds, peptides and proteins. Many work were published, including that a polymer molecule (pentadecafluorooctamido propyltrimethoxysilane) was synthesized, to significantly improve the sensitivity of MALDI-TOF MS analysis in proteomics. During his post-doctoral appointment (Aug 2005-Mar 2012) at Lerner Research Institute Cleveland Clinic Foundation, and Indiana University School of Medicine, Zhenwen Zhao developed a highly effective and sensitive method, which based on HPLC-electrospray ionization mass spectrometry (HPLC-ESI-MS), to analyze lipids in body fluid, and demonstrated, for the first time, that the level of lysophosphatidylcholine (LPC) in plasma is a potential marker for the early detection of colorectal cancer (CRC), which is extremely important for patient with CRC to improve 5-year relative survival rate. Zhenwen Zhao also found that phospholipase A2 (PLA2）enzyme activity is significantly elevated in ovarian cancer tumor, and PLA2 activity specific inhibitors are highly effective in blocking ovarian cancer development. His work is getting published in well-respected peer-reviewed journals, including J. Clin. Oncol., Am. J. Pathol., FASEB J., J. Lipid Res.,etc.